| Trial ID: | L2297 |
| Source ID: | NCT00568074
|
| Associated Drug: |
Repaglinide
|
| Title: |
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: Glurenorm®|DRUG: Glucobay®
|
| Outcome Measures: |
Primary: HbA1c, after 3 months of treatment | Secondary: fasting blood glucose|hypoglycaemia episodes|adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
131
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-12-16
|
| Completion Date: |
2004-09-02
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-20
|
| Locations: |
Novo Nordisk Investigational Site, Shanghai, Shanghai, 200025, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200433, China|Novo Nordisk Investigational Site, Chengdu, Sichuan, 610041, China|Novo Nordisk Investigational Site, Beijing, 100029, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00568074
|
